Modulation of AMPA receptors in spinal motor neurons by the neuroprotective agent riluzole
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
We investigated the interaction of riluzole, a therapeutic agent used in amyotrophic lateral sclerosis (ALS), with α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazole propionic acid (AMPA) receptor channels in mouse spinal motor neurons in culture using whole‐cell patch‐clamp recording techniques. Kainate elicited concentration‐dependent (EC 50 = 35 μM) inward currents in all the patched cells. These responses were mediated primarily through the activation of AMPA receptors with a negligible contribution from kainate receptors, because bath application of 100 μM GYKI53655, a potent noncompetitive AMPA receptor antagonist, completely blocked the kainate‐induced currents. Riluzole (0.5–100 μM) reduced in a dose‐dependent manner the kainate‐induced currents with an IC 50 of 1.54 μM in all tested neurons (n = 25) and this effect was found to be reversible. The response to kainate decreased in the presence of 1 μM riluzole in all spinal motor neurons tested, without changing its EC 50, indicating a noncompetitive mechanism of inhibition. The amplitude of the responses induced by kainate under control condition and during riluzole was a linear function of the membrane potential. The reversal potential of the current was not significantly different in the two experimental conditions, whereas the total conductance of the motor neurons for the currents induced by 100 μM kainate was reduced significantly in the presence of 1 μM riluzole (P < 0.05). These results reveal an interaction of riluzole with glutamatergic neurotransmission in spinal cord motor neurons and can contribute to explain its beneficial effect in the ALS treatment. © 2004 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Glutamate Receptor Ion Channels
Dingledine, R., Borges, K., Bowie, D., & Traynelis, S. F. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01394-2 · Cited by 3,554 · cited 6×
“They are heteromeric complexes composed of various combinations of four subunits, GLUR1 to GLUR4 (Hollmann and Heinemann, 1994; Dingledine et al., 1999).”
BackgroundInfluentialDose-ranging study of riluzole in amyotrophic lateral sclerosis
Amyotrophic Lateral Sclerosis/Riluzole Study Group II, Lacomblez, L., Bensimon, G., Meininger, V, Leigh, P. N., & Guillet, P. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91680-3 · Cited by 1,301
Geiger, J. R. P., Melcher, T., Koh, D.-S., Sakmann, B., Seeburg, P. H., Jonas, P., & Monyer, H. (1995) · Neuron · doi:10.1016/0896-6273(95)90076-4 · Cited by 1,260
Burnashev, N., Monyer, H., Seeburg, P. H., & Sakmann, B. (1992) · Neuron · doi:10.1016/0896-6273(92)90120-3 · Cited by 1,087
The Role of Excitotoxicity in Neurodegenerative Disease
Doble, A. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00042-4 · Cited by 723 · cited 2×
“Its neuroprotective effect, which has been shown both in vivo and in vitro (Peluffo et al., 1997; Gurney et al., 1998), is believed to be beneficial in various neurodegenerative diseases and amelioration of trauma and stroke (Doble, 1999; Rosas et al., 1999; Siniscalchi et al., 1999).”
BackgroundJonas, P. (1994) · Neuron · doi:10.1016/0896-6273(94)90444-8 · Cited by 666 · cited 11×
“These results reveal an interaction of riluzole with glutamatergic neurotransmission in spinal cord motor neurons and can contribute to explain its beneficial effect in the ALS treatment.”
BackgroundInfluentialGlutamate-operated channels: Developmentally early and mature forms arise by alternative splicing
Monyer, H., Seeburg, P. H., & Wisden, W. (1991) · Neuron · doi:10.1016/0896-6273(91)90176-z · Cited by 568
Lambolez, B., Ropert, N., Perrais, D., Rossier, J., & Hestrin, S. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.5.1797 · Cited by 147 · cited 1×
“…permeability (Burnashev et al., 1992; Jonas et al., 1994; Geiger et al., 1995) and alternative flip or flop splicing of all subunits generates further diversity (Monyer et al., 1991; Better and Mulle, 1995) affecting the kinetic properties of AMPAR (Mosbacher et al., 1994; Lambolez et al., 1996).”
Background
Cited by
Stress, Depression, and Neuroplasticity: A Convergence of Mechanisms
Pittenger, C., & Duman, R. S. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301574 · Cited by 1,795
The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis
Van Den Bosch, L., Van Damme, P., Bogaert, E., & Robberecht, W. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2006.05.002 · Cited by 491
Heckman, C. J., & Enoka, R. M. (2012) · Comprehensive Physiology · doi:10.1002/cphy.c100087 · Cited by 414
Riluzole, Neuroprotection and Amyotrophic Lateral Sclerosis
Cheah, B. C., Vucic, S., Krishnan, A., & Kiernan, M. C. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710791163939 · Cited by 258
Riluzole in the Treatment of Mood and Anxiety Disorders
Pittenger, C., Coric, V., Banasr, M., Bloch, M., Krystal, J. H., & Sanacora, G. (2008) · CNS Drugs · doi:10.2165/00023210-200822090-00004 · Cited by 177
Metadata
- Authors
- Albo, F., Pieri, M., & Zona, C.
- Venue
- Journal of Neuroscience Research
- Publisher
- Wiley
- Published
- 2004-09-09
- Volume
- 78
- Issue
- 2
- Pages
- 200-207
- ISSN
- 0360-4012 (ISSN-L)
- 1097-4547
- OpenAlex
- W1971330544
- Cited by
- 61
- References
- 8
- FWCI
- 1.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.